IDH1 and acute myeloid leukemia: Currently, mutations in epigenetic regulators, such as IDH1/2 and DNMT3A, in AML patients serve as molecular predictors of a good response to therapy with hypomethylating agents (HMA) such as Azacitidine or Decitabine.